Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prianka Singh

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Future Oncology (London, England)|March 28, 2023
Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter studyTrang H Au, Connor Willis, Maija Reblin, et al.
Future Oncology (London, England)|April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The New England Journal of Medicine|March 31, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerRonan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, et al.
Future Oncology (London, England)|March 28, 2023
Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter studyTrang H Au, Connor Willis, Maija Reblin, et al.
Future Oncology (London, England)|April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer)Thomas Yau, Peter R Galle, Thomas Decaens, et al.
Lancet (London, England)|May 11, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialThomas Yau, Peter R Galle, Thomas Decaens, et al.
Pageof 3